De Jonge MJ - Search Results

1

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Meulendijks D, et al. Among authors: de jonge mj. Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9. Clin Cancer Res. 2017. PMID: 28600476 Clinical Trial.

2

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Gerrits CJ, et al. Among authors: de jonge mj. Br J Cancer. 1997;76(7):952-62. doi: 10.1038/bjc.1997.491. Br J Cancer. 1997. PMID: 9328159 Free PMC article. Review.

3

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.

de Jonge MJ, Sparreboom A, Planting AS, van der Burg ME, de Boer-Dennert MM, ter Steeg J, Jacques C, Verweij J. de Jonge MJ, et al. Among authors: de boer dennert mm. J Clin Oncol. 2000 Jan;18(1):187-94. doi: 10.1200/JCO.2000.18.1.187. J Clin Oncol. 2000. PMID: 10623709 Clinical Trial.

4

Topotecan lacks third space sequestration.

Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A. Gelderblom H, et al. Among authors: de jonge mj. Clin Cancer Res. 2000 Apr;6(4):1288-92. Clin Cancer Res. 2000. PMID: 10778953 Clinical Trial.

5

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

de Jonge MJ, Loos WJ, Gelderblom H, Planting AS, van der Burg ME, Sparreboom A, Brouwer E, van Beurden V, Mantel MA, Doyle E, Hearn S, Ross G, Verweij J. de Jonge MJ, et al. J Clin Oncol. 2000 May;18(10):2104-15. doi: 10.1200/JCO.2000.18.10.2104. J Clin Oncol. 2000. PMID: 10811676 Clinical Trial.

6

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ. Loos WJ, et al. Among authors: de jonge mj. Clin Cancer Res. 2000 Jul;6(7):2685-9. Clin Cancer Res. 2000. PMID: 10914710

7

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, Jackman A, Smith R, de Mulder PH, Verweij J. de Jonge MJ, et al. Among authors: de mulder ph. J Clin Oncol. 2002 Apr 1;20(7):1923-31. doi: 10.1200/JCO.2002.07.057. J Clin Oncol. 2002. PMID: 11919253 Clinical Trial.

8

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

Ten Tije AJ, Verweij J, Sparreboom A, Van Der Gaast A, Fowst C, Fiorentini F, Tursi J, Antonellini A, Mantel M, Hartman CM, Stoter G, Planting AS, De Jonge MJ. Ten Tije AJ, et al. Among authors: de jonge mj. Clin Cancer Res. 2003 Aug 1;9(8):2957-64. Clin Cancer Res. 2003. PMID: 12912942 Clinical Trial.

9

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C. Gelderblom H, et al. Among authors: de jonge mj. Clin Cancer Res. 2003 Sep 15;9(11):4101-7. Clin Cancer Res. 2003. PMID: 14519632 Clinical Trial.

10

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

151 results

Search Page